Development of Dual-Targeting CAR-T Cells for Enhanced Specificity and Efficacy in Solid Tumors

Research Proposal:
Development of Dual-Targeting CAR-T Cells for Enhanced Specificity and Efficacy in Solid Tumors

Jeya Chelliah B.Vsc Ph.D.

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies, achieving remarkable success in patients with acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). However, its application in solid tumors remains a challenge due to issues such as tumor heterogeneity, immune suppression in the tumor microenvironment, and potential off-target toxicity.


The primary objective of this research is to develop a dual-targeting CAR-T cell therapy that can recognize and eliminate solid tumor cells with higher specificity and reduced off-target effects. The project aims to combine two different CAR constructs that recognize distinct tumor-associated antigens, leading to T-cell activation only when both antigens are present on the target cell.


We hypothesize that dual-targeting CAR-T cells will have:

  1. Enhanced specificity: Reduced binding to normal tissues expressing only one of the target antigens.
  2. Increased efficacy: Overcoming the tumor heterogeneity by targeting multiple antigens.


  1. Target Identification and Validation
    • Conduct genome-wide expression analysis to identify tumor-specific antigens that are overexpressed in a wide range of solid tumors.
    • Validate the targets using immunohistochemistry in patient tissue samples.
  1. CAR Construct Design
    • Develop two separate CAR constructs targeting the identified antigens.
    • Engineer a single T-cell to express both CAR constructs.
  1. In Vitro Validation
    • Evaluate the specificity and cytotoxicity of dual-targeting CAR-T cells against a panel of tumor cell lines using flow cytometry and killing assays.
  1. In Vivo Studies
    • Utilize mouse models to evaluate the efficacy, biodistribution, and potential toxicity of the dual-targeting CAR-T cells.
  1. Clinical Translation
    • Phase I/II clinical trials to evaluate safety and preliminary efficacy in human subjects.

Expected Outcomes

  1. Development of dual-targeting CAR-T cells with reduced off-target toxicity.
  2. Demonstration of the efficacy of dual-targeting CAR-T cells in preclinical models.
  3. Initiation of clinical trials for further validation.


  • Year 1: Target identification and validation
  • Year 2: CAR construct design and in vitro validation
  • Year 3: In vivo studies and preparation for clinical trials
  • Year 4-5: Phase I/II clinical trials


  • Estimated total cost: $3 million


This project aims to overcome some of the current limitations of CAR-T cell therapy in treating solid tumors by developing a novel dual-targeting approach. If successful, this research could pave the way for more effective and safer immunotherapies for a wide range of cancers.

This research idea is novel and builds on existing knowledge of CAR-T cell therapy, aiming to tackle the specific challenges associated with treating solid tumors. It has the potential for high impact and could open new avenues for cancer immunotherapy

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign up to Stay in Touch!
About eScience Info’s Newsletter This is a free weekly eNewsletter for Life Science Scientists. eScienceInfo has established itself as the leading provider of up-to-the-minute information for Scientists. Now, we’re enhancing our services to better meet the needs of our readers. For years we’ve searched out the latest grants available and consolidated the information into one easy-to-read e-newsletter. Then we delivered it right to your inbox to save you the hundreds of hours that it would take to search out that information yourself.
By submitting this form, you are consenting to receive marketing emails from: eScience Info LLC, 4990 Sadler Place , Unit #4982, GLEN ALLEN, VA 23058-1323, US, http://www.escienceinfo.com You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact.